Ono Pharmaceutical Co. Ltd. (ON4)
Munich
12.77
-0.06 (-0.47%)
Closed
Oct 8, 2026
Day's Range
12.7712.77
52 wk Range
9.6014.60
Financial Statements - ON4 - Ono Pharmaceutical Co. Ltd.
Revenue
515.78B▲ 5.9%
Net Income
69.91B▲ 39.4%Net Margin 13.6%
EBITDA
133.94B▲ 46.3%
Free Cash Flow
83.55B▲ 12.2%
Income Statement
| Period Ending | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
|---|---|---|---|---|---|---|
| Sales | 515.78B | 486.87B | 502.67B | 447.18B | 361.36B | 309.28B |
| Cost of Goods | 141.71B | 147.95B | 127.12B | 110.06B | 93.51B | 85.57B |
| Gross Profit | 374.06B | 338.92B | 375.54B | 337.12B | 267.85B | 223.71B |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | 92.23B | 59.74B | 159.93B | 141.96B | 103.19B | 98.33B |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | - | - | - | - | - | - |
| Pre Tax Income | 92.65B | 59.32B | 163.73B | 143.53B | 105.02B | 100.89B |
| Income Tax | 22.74B | 9.16B | 35.69B | 30.61B | 24.34B | 25.39B |
| Net Income | 69.91B | 50.16B | 128.04B | 112.91B | 80.68B | 75.49B |
| EPS Basic | 148.49 | 106.55 | 266.61 | 230.85 | 162.19 | 151.11 |
| EPS Diluted | 148.41 | 106.41 | 266.57 | 230.79 | 162.16 | 151.09 |
| Basic Shares Outstanding | 469.84M | 469.70M | 480.01M | 488.30M | 79.05B | 79.48B |
| Diluted Shares Outstanding | 469.84M | 469.70M | 480.01M | 488.30M | 79.05B | 79.48B |
| Ebit | 96.19B | 64.64B | 163.96B | 144.44B | 105.89B | 101.02B |
| Ebitda | 133.94B | 91.54B | 182.10B | 161.89B | 123.62B | 116.84B |
| Net Income Continuous Operations | 92.65B | 59.32B | 163.73B | 143.53B | 105.02B | 100.89B |
| Minority Interests | -144M | -119M | -62M | -190M | -166M | -72M |
| Preferred Stock Dividends | 0 | 0 | 0 | 0 | 0 | 0 |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
